MedCap

About MedCap

MedCap is a Stockholm-listed life-science investment company with approximately SEK 2.05 billion of net asset value as of December 2024 (FY2024 revenue SEK 1,807 million), headquartered in Stockholm at Engelbrektsgatan 9-11. The firm was founded in 2001 and is listed on Nasdaq Stockholm Mid Cap (ticker MCAP), operating as a permanent-capital balance-sheet investor that owns operating subsidiaries directly rather than via closed-end funds.

Investment thesis

MedCap deploys capital through a single listed vehicle holding approximately 11-12 portfolio subsidiary companies across three business areas, targeting active long-term majority ownership of profitable, market-leading niche life-science companies in Northern Europe scaled via buy-and-build. Sector focus spans assistive technology, medical technology (MedTech), specialty pharmaceuticals, healthcare equipment, monitoring and safety devices and life-science packaging. Geographic deployment is Nordics core (Sweden, Denmark, Norway) plus UK with international growth ambition. The platform is one of the few Stockholm-listed pure-play life-science compounders.

Recent activity

As a permanent-capital holder, MedCap rarely divests, with no notable disposals identified in 2024-2026. Recent acquisitions include healthcare monitoring and safety devices (2025, via Abilia: Picomed in Norway, Alert-it/ITS Designs in UK) and assistive-tech distribution (Kompany, Norway). The platform continues active deployment across the Northern European life-science compounding mandate. Detailed buyer names and multiple data available on Pro at €49/month.